Drug intelligence / Profile preview

iodixanol, ioversol, iopromide

Development stage: Unknown
Lead developer: GE Healthcare
Modality: Small Molecules
Administration: Intravenous, Intra-arterial

Overview

This input is not a single drug entity; it names **three distinct nonionic iodinated X-ray contrast agents**: iodixanol, ioversol, and iopromide. These injectable diagnostic agents increase radiographic contrast by attenuating X-rays within the blood vessels, cardiac chambers, urinary tract, and other perfused structures during angiography and contrast-enhanced CT. Iodixanol is a dimeric iso-osmolar agent, whereas ioversol and iopromide are low-osmolar monomeric agents. The cited GE HealthCare-sponsored clinical study compared their effects on renal function after contrast administration in patients at risk of kidney injury. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00335101))

Other names: iodixanolioversoliopromide

Beyond the preview

Go deeper on iodixanol, ioversol, iopromide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iodixanol, ioversol, iopromide.

Explore the full profile